Fig. 8
Anti-tumor effect of CIGB-300 administered by intravenous injection in a cell line-based NCI-H226 xenograft tumor model. Two cycles of 5-consecutive injections of CIGB-300 at 2 mg/kg or 10 mg/kg were injected by the tail vein and Tumor Growth (a) or Survival (b) scored until day 16 or day 40, respectively. At day 16, two mice per group were sacrificed for IHC analysis on tumor mass using indicated antibodies (c), whereas the rest were maintained for survival analysis (n = 4). In (a), ∆ indicate peptide injections. At every time-point, Tumor Volume (means ± SD) of CIGB-300-treated mice were compared against Vehicle-treated mice by one-way ANOVA followed by Dunnett multiple comparison test and denoted when significant ( * p < 0.05, * * p < 0.01). For survival analysis (b), Kaplan-Meier Curves were compared by a Logrank (p = 0.0022) and Logrank test for trend (p = 0.0005), as well as by individual pair-wise comparison against Vehicle-treated mice and denoted when significant (** p < 0.01). Median survival in days (d) for each experimental group is also shown. In (c), representative IHC pictures and staining scores are shown as insert (mean ± SD). No statistical analysis was done since only 2 mice per group were analyzed here (Supplementary Table S3 online).
